Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

Document first published:
Page updated:
Topic:
,
Publication type:

Document

Clinical Commissioning Policy Statement: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

Clinical Commissioning Policy Statement: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

  • PDF
  • 48 KB
  • 3 pages

Document

Clinical priorities advisory group: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

Clinical priorities advisory group: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

  • PDF
  • 45 KB
  • 3 pages

Document

Evidence review: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

Evidence review: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

  • PDF
  • 58 KB
  • 5 pages

Document

Compliance with equality / inequalities legislation in the formation of clinical commissioning policy propositions: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

Compliance with equality / inequalities legislation in the formation of clinical commissioning policy propositions: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

  • PDF
  • 41 KB
  • 2 pages

Document

Engagement report: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

Engagement report: Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)

  • PDF
  • 77 KB
  • 3 pages